We are live on
!
Find out more
APM
Avidity Partners Management Portfolio holdings
AUM
$624M
Turnover
44.83%
1-Year Est. Return
250.2%
This Fund
S&P 500
This Quarter
Est. Return
+6.68%
1 Year Est. Return
+250.2%
3 Year Est. Return
+491.63%
5 Year Est. Return
+985.37%
10 Year Est. Return
–
AUM
$2.16B
AUM Growth
+$596M
(+38%)
Cap. Flow
+$355M
Cap. Flow
% of AUM
16.46%
Top 10 Holdings %
Top 10 Hldgs %
48.34%
Holding
102
New
45
Increased
15
Reduced
8
Closed
34
Avg Time Held Equity + Options
0.1
years
Top 10 Avg Time Held Equity + Options
0.2
years
Top 20 Avg Time Held Equity + Options
0.2
years
Avg Time Held Equity only
0.1
years
Top 10 Avg Time Held Equity only
0.2
years
Top 20 Avg Time Held Equity only
0.2
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Merck
MRK
|
+$93.9M |
| 2 |
Biogen
BIIB
|
+$87.9M |
| 3 |
Akebia Therapeutics
AKBA
|
+$64.3M |
| 4 |
Avantor
AVTR
|
+$61.3M |
| 5 |
Thermo Fisher Scientific
TMO
|
+$48.9M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Regeneron Pharmaceuticals
REGN
|
+$82.4M |
| 2 |
IMMU
Immunomedics Inc
IMMU
|
+$67.7M |
| 3 |
ALXN
Alexion Pharmaceuticals
ALXN
|
+$57M |
| 4 |
Hologic
HOLX
|
+$46.6M |
| 5 |
Exelixis
EXEL
|
+$44.9M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 81.27% |
| 2 | Miscellaneous | 16.95% |
| 3 | Technology | 1.7% |
| 4 | Industrials | 0.07% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
1
CALL
Pfizer
PFE
$168B
| $239M | 11.06% |
+6,851,000
| New | +$240M |
2020 Q3
0 quarters
|
|
2
AbbVie
ABBV
$501B
| $133M | 6.19% |
1,522,800
-22,600
| -1% | -$2.13M |
2019 Q4
3 quarters
|
|
|
SGEN
3
DELISTED
Seagen Inc. Common Stock
SGEN
| $104M | 4.82% |
531,100
+280,200
| +112% | +$46.9M |
2020 Q1
2 quarters
|
|
|
4
Avantor
AVTR
$10.9B
| $103M | 4.76% |
4,562,400
+2,950,400
| +183% | +$61.3M |
2020 Q2
1 quarter
|
|
|
5
Merck
MRK
$358B
| $94.9M | 4.4% |
+1,199,226
| New | +$93.9M |
2020 Q3
0 quarters
|
|
|
6
Biogen
BIIB
$34.8B
| $89.4M | 4.15% |
+315,100
| New | +$87.9M |
2020 Q3
0 quarters
|
|
7
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
| $83.5M | 3.87% |
1,284,200
+179,700
| +16% | +$11.8M |
2020 Q1
2 quarters
|
|
|
HZNP
8
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $72.3M | 3.35% |
930,200
+394,000
| +73% | +$27.1M |
2019 Q4
3 quarters
|
|
9
NovaBridge Biosciences American Depositary Shares
NBP
$149M
| $63M | 2.92% |
+1,340,000
| New | +$44.2M |
2020 Q3
0 quarters
|
|
|
10
CALL
Biogen
BIIB
$34.8B
| $60.7M | 2.82% |
+214,100
| New | +$59.7M |
2020 Q3
0 quarters
|
|
11
Aurinia Pharmaceuticals
AUPH
$2.23B
| $52.5M | 2.44% |
3,564,900
+1,090,301
| +44% | +$15.8M |
2019 Q4
3 quarters
|
|
|
12
Thermo Fisher Scientific
TMO
$258B
| $52.2M | 2.42% |
+118,300
| New | +$48.9M |
2020 Q3
0 quarters
|
|
13
DELISTED
Bristol-Myers Squibb Company Contingent Value Rights
BMY.RT
| $51M | 2.37% |
22,684,932
+16,897,991
| +292% | +$48.3M |
2020 Q2
1 quarter
|
|
14
Baxter International
BAX
$13.3B
| $49.9M | 2.31% |
620,000
-180,900
| -23% | -$15.2M |
2020 Q2
1 quarter
|
|
15
Elevance Health
ELV
$92.9B
| $47.4M | 2.2% |
+176,400
| New | +$47.5M |
2020 Q3
0 quarters
|
|
16
Quest Diagnostics
DGX
$26.4B
| $46M | 2.13% |
+402,000
| New | +$47.5M |
2020 Q3
0 quarters
|
|
|
MRTX
17
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $45.7M | 2.12% |
+275,000
| New | +$37.6M |
2020 Q3
0 quarters
|
|
18
QuidelOrtho
QDEL
$954M
| $38.8M | 1.8% |
+176,879
| New | +$39.5M |
2020 Q3
0 quarters
|
|
19
Boston Scientific
BSX
$64B
| $37M | 1.71% |
+967,100
| New | +$37.3M |
2020 Q3
0 quarters
|
|
|
CHNG
20
DELISTED
Change Healthcare Inc. Common Stock
CHNG
| $36.7M | 1.7% |
+2,527,500
| New | +$32.1M |
2020 Q3
0 quarters
|
|
21
Natera
NTRA
$58.3B
| $36.4M | 1.69% |
+503,400
| New | +$28.6M |
2020 Q3
0 quarters
|
|
|
KDMN
22
DELISTED
Kadmon Holdings, Inc.
KDMN
| $35.4M | 1.64% |
9,030,000
+2,603,300
| +41% | +$10.9M |
2019 Q4
3 quarters
|
|
23
Arvinas
ARVN
$468M
| $31.8M | 1.48% |
1,348,300
+271,400
| +25% | +$7.87M |
2020 Q2
1 quarter
|
|
24
Zentalis Pharmaceuticals
ZNTL
$212M
| $29.6M | 1.37% |
904,119
+229,632
| +34% | +$8.04M |
2020 Q2
1 quarter
|
|
25
Syndax Pharmaceuticals
SNDX
$1.22B
| $27.4M | 1.27% |
1,854,100
+326,700
| +21% | +$4.98M |
2020 Q2
1 quarter
|
|
Similar funds
ANB
CWM
RIP
TAM
B
PWS
LWP
TAA
Avidity Partners Management's Q3 2020 Portfolio in Review
As of Q3 2020, Avidity Partners Management held 102 positions worth $2.16B, up 38% from $1.56B the previous quarter. Its ten largest holdings account for 48% of the portfolio.
Avidity Partners Management deployed $355M of net new capital in Q3 2020, opening 45 new positions and adding to 15 existing holdings. Its largest new stake was Merck: 1,199,226 shares worth $94.9M.
By sector, the portfolio is most concentrated in Healthcare at 81% of assets, down from 99% a quarter earlier, followed by Miscellaneous and Technology.
On the sell side, the largest reduction was Exelixis, an estimated $44.9M trimmed.
- Avidity Partners Management's largest Q3 2020 buy was Merck: 1,199,226 shares worth $94.9M.
- Avidity Partners Management added most to Avantor in Q3 2020, an estimated $61.3M increase.
- Avidity Partners Management's biggest Q3 2020 reduction was Exelixis, cutting an estimated $44.9M.
- Avidity Partners Management fully exited Regeneron Pharmaceuticals in Q3 2020, selling an estimated $82.4M.
- Avidity Partners Management's ten largest holdings make up 48% of its $2.16B portfolio in Q3 2020.
- Avidity Partners Management opened 45 new positions and closed 34 in Q3 2020.
- Avidity Partners Management's portfolio value rose 38% quarter-over-quarter to $2.16B.
Based on Avidity Partners Management's 13F filing for Q3 2020, filed 16 Nov 2020.